Evidence is rising in favor of using highly effective DMTs to treat pediatric MS, but with few licensed for pediatric use, it ...

This year, it has been joined by natalizumab (Tysabri; Elan/Biogen-Idec), a humanized antibody against α4 integrin, and most recently, the PEGylated humanized anti-TNF-α antibody fragment ...

The patient sentiment towards the multiple sclerosis drug Tysabri (natalizumab), which was linked with three cases of progressive multifocal leukoencephalopathy (PML) in July and October of 2008 ...

Interferon and natalizumab were initially used less frequently, but their usage equalized over time (OR 0.99 [95% CI 0.92–1.06], OR 0.96 [95% CI 0.86-1.06], respectively). In contrast ...

"The acceptance of the filing of proposed biosimilar natalizumab by the European regulatory authorities means we are a critical step closer to getting this important medicine to the patients who ...

Unjustified fears about harm in pregnancy is preventing the use of highly effective medications in women with MS, new ...

New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...

Patients with high sNfL levels often did not respond well to standard disease-modifying treatments (DMTs) but showed significant benefits from high-efficacy DMTs (HE-DMTs) such as natalizumab, ...

Patients with high sNfL levels often did not respond well to standard disease-modifying treatments (DMTs) but showed significant benefits from high-efficacy DMTs (HE-DMTs) such as natalizumab ...

New research presented today at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term ...

This is really important, because there have been case reports of patients experiencing relapses with natalizumab and fingolimod when they've discontinued the medication. That's why it's important for ...

TA972 22 May 2024 22 May 2024 Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome HST31 22 May 2024 22 May 2024 Natalizumab for the treatment of adults with highly active ...